Journal
JOURNAL OF IMMUNOLOGY
Volume 192, Issue 4, Pages 1641-1650Publisher
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1302672
Keywords
-
Categories
Funding
- Colorado Bioscience Discovery Evaluation grant program
- National Institutes of Health [P01 AI022295, R01 AI077597]
Ask authors/readers for more resources
B cells play a major role in the pathogenesis of many autoimmune disorders, including rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, and type I diabetes mellitus, as indicated by the efficacy of B cell-targeted therapies in these diseases. Therapeutic effects of the most commonly used B cell-targeted therapy, anti-CD20 mAb, are contingent upon long-term depletion of peripheral B cells. In this article, we describe an alternative approach involving the targeting of CD79, the transducer subunit of the B cell AgR. Unlike anti-CD20 mAbs, the protective effects of CD79-targeted mAbs do not require cell depletion; rather, they act by inducing an anergic-like state. Thus, we describe a novel B cell-targeted approach predicated on the induction of B cell anergy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available